Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4471-4473

  Zvada, Simbarashe P ^a   Denti, Paolo ^a   Geldenhuys, Hennie ^b   Meredith, Sandra ^a   Van As, Danelle ^b   Hatherill, Mark ^b   Hanekom, Willem ^b   Wiesner, Lubbe ^a   Simonsson, Ulrika S H ^c   Jindani, Amina ^d   Harrison, Thomas ^d   McIlleron, Helen M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UPPSALA UNIVERSITY   (Sweden)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; RIFAPENTINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; HUMAN; LUNG TUBERCULOSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84864387240     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00404-12     Document Type: Article

References (19)

1. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
2. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24:25-36.
3. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2009. NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City, MD.
4. Beal SL, Sheiner LB, Boeckmann A. 1996. NONMEM user's guides. NONMEM Project Group, University of California, San Francisco, San Francisco, CA.
5. Bliven-Sizemore E, et al. 2011. CYP3A induction by rifampin and rifapentine: which drug and dose does it best?, abstr O-04 Abstr. 4th Int. Workshop Clin. Pharmacol. Tuberc. Drugs, Chicago, IL, 16 September 2011. http://regist2.virology-education.com/abstractbook/4th-TB-PK.pdf.
6. Brillault J, et al. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 53:1457-1462.
7. Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341. (Pubitemid 32565595)
8. Dooley K, et al. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52:4037-4042.
9. Heifets LB, Lindholm-Levy PJ, Flory MA. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630. (Pubitemid 20109150)
10. Holford N. 2005. The visual predictive check - superiority to standard diagnostic (Rorschach) plots, abstr 738. Abstr. 14th Meet. Popul. Approach Group Eur. (PAGE).
11. Hu Y, Coates AR, Mitchison DA. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657. (Pubitemid 36158096)
12. Ji B, et al. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069. (Pubitemid 28363094)
13. Jonsson EN, Karlsson MO. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
14. Nijland HM, et al. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45:1001-1007. (Pubitemid 47580349)
15. Peloquin CA, et al. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857. (Pubitemid 351358362)
16. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
17. Senggunprai L, Yoshinari K, Yamazoe Y. 2009. Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab. Dispos. 37:1711-1717.
18. Siefert HM, et al. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl B):69-76. (Pubitemid 29231796)
19. Tachibana M, Tanaka M, Masubuchi Y, Horie T. 2005. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab. Dispos. 33:803-811. (Pubitemid 40686634)